What is the current stock price of DiaSorin S.p.A. (DSRLF)?

As of the latest market data, DiaSorin S.p.A. (DSRLF) is trading at $67.00. The stock has seen a loss of 0.00% today.

Does DiaSorin S.p.A. (DSRLF) pay a dividend?

Based on current data, DiaSorin S.p.A. does not have a confirmed active dividend policy.

What is the market cap of DiaSorin S.p.A.?

The current market capitalization of DiaSorin S.p.A. (DSRLF) is approximately unavailable.

DSRLF

DiaSorin S.p.A.·Healthcare

67.00

0.000%(+0.00)

Market Closed

76.74

14.537%(+9.74)

After Hours

Last Updated: — ET

52W L: $66.5052W H: $112.30

DSRLF NEWS

defenseworld.net

Apr 6

Head to Head Contrast: Perrigo (NYSE:PRGO) and DiaSorin (OTCMKTS:DSRLF)

DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Perrigo (NYSE: PRGO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Analyst Ratings This is a summary of current ratings and

seekingalpha.com

Mar 20

DiaSorin S.p.A. (DSRLF) Q4 2025 Earnings Call Transcript

defenseworld.net

Jan 26

Head-To-Head Survey: Abbott Laboratories (NYSE:ABT) vs. DiaSorin (OTCMKTS:DSRLF)

DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Abbott Laboratories (NYSE: ABT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Risk and Volatility DiaSorin has a beta of 0.1,

Company Profile

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

3,249

IPO Date

2009-09-11

Beta

0.70

Websitediasoringroup.com↗